Effect of tyramine in migraine: a double-blind study

ADRIENNE MOFFETT, MICHAEL SWASH, AND D. F. SCOTT

From the Departments of Neurology and EEG, Section of Neurological Sciences, The London Hospital, London

SUMMARY The incidence of headache and changes in the EEG after tyramine were studied in 25 migrainous patients in a double-blind placebo-controlled investigation. There were three groups of patients: the first had migraine alone, the second had migraine and epilepsy, and the third had migraine which was precipitated by food substances containing tyramine. Psychological tests showed that all the patients were more neurotic, more introverted, and more obsessional than normal subjects. Headache occurred in 12 of 50 patient sessions and 10 of these occurred in the group with dietary precipitated migraine. In this group, however, headache followed tyramine alone in only two patients. The remaining eight headaches occurred in two patients after placebo alone, and in three after both test capsules. The EEG was activated after tyramine, but not after placebo, in 11 of the 15 patients with migraine and epilepsy, and dietary precipitated migraine. This effect was observed, however, in only two of the 10 patients with classical migraine alone. There was no relation between the occurrence of headache and EEG activation. Although there was no significant relationship between tyramine ingestion and the occurrence of headache, the EEG changes observed during the study support the hypothesis that tyramine has an action on the central nervous system in some migrainous subjects.

About 5% of migrainous subjects notice that certain foods, known to contain large amounts of free tyramine, may induce typical migraine headache. Indeed, Hanington (1967, 1969), and Hanington, Horn, and Wilkinson (1970) have shown that about 70% of these subjects develop typical migraine headache three to 18 hours after the ingestion of 125 mg tyramine. Youdim, Carter, Sandler, Hanington, and Wilkinson (1971) have suggested that the headache-inducing effect of tyramine may be due to defective conjugation of ingested tyramine in the intestinal wall of susceptible individuals. Further, dietary tyramine is known to induce hypertension and headache in non-migrainous patients taking monoamine oxidase inhibitor drugs (Blackwell and Mabbitt, 1965) and this effect has been shown to be due to inhibition, by these drugs, of intestinal and hepatic breakdown of dietary tyramine so that large amounts of tyramine, which is a pressor substance, accumulate (Blackwell and Marley, 1964; Tedeschi and Fellows, 1964). However, none of Hanington's patients was hypertensive at the time of their tyramine-induced headaches and none was taking monoamine oxidase inhibitor drugs (Hanington, 1967, 1969). The mechanism of action of tyramine in migraine is uncertain and Blau (1971) has pointed out that, if this were a pharmacological effect, the variable delay between ingestion of tyramine and the occurrence of headache would be most unusual.

The electroencephalograms (EEGs) of migrainous subjects may be markedly abnormal during an attack (Slatter, 1968) but it is a well established, and yet a poorly understood observation, that the resting EEGs of migrainous subjects are also frequently abnormal, containing poorly organized background activity and excessive amounts of both generalized and localized theta activity (Slatter, 1968). These changes are similar to those found in the interictal recordings of epileptic patients (Slatter, 1968; Basser, 1969) and it seemed a possibility that if tyramine induced headache in migrainous subjects it would increase the pre-existing EEG abnormality. We have therefore examined the role of tyramine in migraine in more detail using serial EEG recordings as well as clinical and psychological tests. For this purpose oral tyramine was administered in a double blind placebo controlled study of a group of 25
selected patients with classical migraine, migraine and epilepsy, and migraine with a history of attacks precipitated by foods containing tyramine. In this paper we report the incidence of headache and its relation to changes in the pre-existing EEG abnormalities after tyramine ingestion.

METHODS

Twenty-five women with classical migraine, defined according to the criteria of The World Federation of Neurology (Cochrane, 1970) were studied. Their ages ranged from 20 to 57 years; they all usually had two or more attacks of migraine headache in a single month and they were all otherwise healthy. None of the patients was taking oral contraceptive drugs, but several were taking other regular medication, including diazepam, barbiturates, and ergotamine, and they were allowed to continue this.

The patients were divided into three groups. Group A consisted of 10 patients with migraine alone (mean age 34 years) and group B consisted of seven patients who had both migraine and epilepsy (mean age 35 years). All these patients had previously attended the neurological clinic at The London Hospital for treatment and none gave a history of a dietary precipitant for their migraine. In group C there were eight patients (mean age 38 years) who volunteered for the study because they had noticed that certain foods, known to contain tyramine, could precipitate their headache. The trial was double-blind and placebo controlled and it was fully balanced in groups A and C. In group B, however, an eighth patient with both migraine and epilepsy could not be obtained.

At the initial visit each patient had a full clinical examination to exclude other disease and an EEG recording, and a series of psychological tests was administered. These included a mood scale (Reynolds, Joyce, Swift, Tooley, and Weatherall, 1965), the Eysenck Personality Inventory (Eysenck and Eysenck, 1964), the Leyton Obsessional Inventory (Cooper, 1970), and Raven's Matrices (Raven, 1938). As far as possible these tests were administered at the initial attendance but it was not usually possible to complete them then and the remainder were administered during one of the other visits.

Each patient attended on two subsequent occasions four to seven hours after capsule ingestion, and again, by questionnaire, 48 hours later. The blood pressure was measured at each visit. All the patients completed this schedule satisfactorily.

When the study had been finished the EEGs were coded and masked and then rated independently by M.S. and D.F.S. according to criteria established by these observers in a previous investigation (Swash, Rowan, and Scott, 1971; Swash and Rowan, 1972). The preliminary EEGs, which were taken to familiarize the patients with the procedure, were discarded from this analysis.

RESULTS

Headache occurred after ingestion of a capsule in 12 of 50 patient sessions. One headache followed placebo in group A and one followed tyramine in group B. The remaining 10 headaches occurred in group C. In this group two headaches occurred after tyramine, two after placebo and six, in three patients, after both test capsules. None of the headaches reported during the study was typical of these patients' usual migraine headaches. One spontaneous migraine headache occurred during the study, but this did not interfere with the test schedule. Unfortunately, it was not possible to record an EEG during this attack.

The EEG abnormalities observed in the 50 records studied consisted, in summary, of episodic lateralized frontotemporal theta activity and episodic bilateral theta and delta wave forms at rest. These changes were accentuated by hyperventilation. Frank paroxysmal activity was seen only in the EEGs of epileptic subjects (group B). More severe abnormalities were observed in the EEG records made after tyramine ingestion in five of the seven patients in group B, and in six of the eight patients in group C, but in only two of the 10 patients, in group A (Table). These findings in groups B and C are significantly different from those in group A (P=0.05 < > 0.02). In addition, the specifically epileptic features present in the EEGs of the patients in group B were also activated after

<table>
<thead>
<tr>
<th></th>
<th>Tyramine</th>
<th>Placebo</th>
<th>Both</th>
<th>EEG activated by tyramine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Group B</td>
<td>7</td>
<td>1</td>
<td></td>
<td>5*</td>
</tr>
<tr>
<td>Group C</td>
<td>8</td>
<td>2</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

* P=0·05 < > 0·02
tyramine. All these EEG changes occurred independently of headache and in no instance were EEG abnormalities more marked in those records made after ingestion of lactose placebo than in those made after tyramine ingestion. The EEG abnormalities found in the three groups of patients and details of the nature of the EEG activation observed will be fully described in a subsequent paper (Scott, Moffett, and Swash, 1972).

The psychological tests showed an excess of neuroticism, introversion, and obsessuality in all three groups of patients. These features were most pronounced in groups B and C. In addition the patients in group C had a slightly higher intelligence score than the others. There was no relationship between changes in mood and tyramine ingestion, the occurrence of headache, or EEG activation. No change in blood pressure was noted after tyramine ingestion.

**DISCUSSION**

In their studies of the role of tyramine in migraine Hanington, (1967, 1969) and Hanington et al. (1970) found that 70% of a group of 36 susceptible subjects developed headache after oral tyramine. Although our patients were given the same dose of this substance, only two of the eight patients in group C, who were selected by the same criteria as those used by Hanington, suffered headache after oral tyramine. In addition, two patients in this group reported headache after placebo and three after both tyramine and placebo. Only two of the 12 headaches observed during the whole study occurred in groups A and B and none of these headaches was typical of these patients' usual migraine. The patients in group C differed from those in the other groups. They were all volunteers, self selected by having noticed a tendency for their migraine attacks to be precipitated by dietary factors, and they therefore expected to develop headache after one or both test capsules. In addition, they achieved higher scores in tests of introversion, neuroticism, obsessuality, and intelligence than patients in groups A and B. It is suggested that the high incidence of headache in this group may have been due to the interaction of these various factors rather than to any pharmacological action of lactose or tyramine.

There are a number of other possible explanations for the discrepancy between our results and those of Hanington. One factor might be that the frequent occurrence of placebo headaches was due to the stress of hospital attendances required during the study. That this is an unlikely cause is shown by the absence of headache during the first, and, presumably, most stressful visit and the absence of change in the mood scale scores during the study. Another explanation might be that our subjects failed to take their tyramine-containing test capsule. However, the demonstration of significant EEG activation after tyramine in 13 of our 25 patients, of whom 11 were in groups B and C, which together consisted of 15 patients, is strong evidence against this. Furthermore, the activating effect of tyramine on the EEG was not striking in the patients in group A who had migraine alone. EEG activation occurred after tyramine in only two of the 10 patients in this group.

Although we have not observed a significant number of headaches after tyramine in any of the three groups of migrainous patients studied, the finding of EEG activation after tyramine ingestion suggests that tyramine, one of its metabolites, or a substance released by tyramine can cross the blood brain barrier. This effect was striking in the patients with migraine and epilepsy, and dietary-induced migraine who formed groups B and C, and in both these groups it occurred with a frequency comparable with that of headache in Hanington's patients. There is evidence, therefore, that these patients reacted differently to oral tyramine than did those with classical migraine alone. However, the failure of our patients to develop migraine headache after tyramine remains contrary to Hanington's experience. Since the response to tyramine has not yet been shown to be a pharmacological one (Blau, 1971) it would be worth attempting to confirm Hanington's observations by studying the effect of tyramine at different dosages, using a similar double-blind trial design.

Finally, it should be noted that this study demonstrates, firstly, the importance of a careful double-blind trial design in studies of the effects of pharmacological or therapeutic substances in patients with migraine; secondly, the importance of personality factors in the production of subjective symptoms such as headaches; and, thirdly, the value of serial EEG recordings in pharmacological studies of precipitating factors in migraine.

This work was supported by the Wellcome Trust
who provided a salary for A.M. and incidental expenses. During the study M.S. was in receipt of an M.R.C. grant. We wish to thank Dr. R. A. Henson and Dr. C. J. Earl who allowed us to study their patients and we are especially grateful to Dr. Edda Hanington who referred the patients in group C. We are indebted to the technicians of the EEG department who carried out the recordings and finally to our patients who volunteered to take part in the study. A preliminary report of this work was read at a joint meeting of the Royal Society of Medicine and the Deutsche Gesellschaft für Neurologie in Göttingen on 20 June 1971.

REFERENCES


Effect of tyramine in migraine: a double-blind study

Adrienne Moffett, Michael Swash and D. F. Scott

*J Neurol Neurosurg Psychiatry* 1972 35: 496-499
doi: 10.1136/jnnp.35.4.496

Updated information and services can be found at:
http://jnnp.bmj.com/content/35/4/496

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/